Beacon Endoscopic Corp. has raised $1.2 million in debt financing from existing investors to fund commercial growth for its bnx™ fine needle aspiration for EUS in the US and abroad, company CEO and President Bill Densel said. Beacon made its regulatory filing to the SEC on July 22. The bnx™ system is “designed to reduce procedural waste” and “is intended to significantly reduce per procedure sharps-biohazard disposal waste,” according to the company website.
The remaining $399,401 it seeks will also come from existing investors, Densel said.
The bnx™ system is commercially available in the US, Europe and many countries in the Asia-Pacific region, he said.
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
“In the future Beacon hopes to be able to address obesity, Type II diabetes, gallbladder disease and pancreatic suture drainage,” according to a release.
Before signing on at Beacon, Densel previously served as the GM of CardioSCORE with BG Medicine and CEO of Dune Medical Devices. Other company officers, according to the filing, include Dr. Stephen Reeders, Dr. Christopher Thompson and Co-Founder, Director and VP of Sales and Marketing Brian Tinkham.
